Cipla 향후 성장

Future 기준 점검 1/6

Cipla (는) 각각 연간 10.8% 및 9.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 10.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.6% 로 예상됩니다.

핵심 정보

10.8%

이익 성장률

10.31%

EPS 성장률

Pharmaceuticals 이익 성장	15.7%
매출 성장률	9.5%
향후 자기자본이익률	13.62%
애널리스트 커버리지	Good
마지막 업데이트	24 Jan 2026

최근 향후 성장 업데이트

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Nov 02

Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 16

Recent updates

The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet

Jan 17

We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt

Dec 29

Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?

Nov 20

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Nov 02

Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 16

Cipla Limited (NSE:CIPLA) Investors Are Less Pessimistic Than Expected

Apr 15

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Mar 25

These 4 Measures Indicate That Cipla (NSE:CIPLA) Is Using Debt Safely

Feb 17

Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions

Nov 10 Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.

이익 및 매출 성장 예측

NSEI:CIPLA - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2028	344,244	56,599	41,196	N/A	28
3/31/2027	313,834	49,784	35,047	N/A	33
3/31/2026	283,232	41,747	29,511	N/A	14
12/31/2025	279,672	45,464	N/A	N/A	N/A
9/30/2025	279,658	54,411	27,544	42,949	N/A
6/30/2025	274,796	53,925	N/A	N/A	N/A
3/31/2025	272,674	52,725	34,653	50,050	N/A
12/31/2024	267,201	49,897	N/A	N/A	N/A
9/30/2024	262,642	44,751	29,520	45,008	N/A
6/30/2024	258,922	43,035	N/A	N/A	N/A
3/31/2024	255,367	41,216	27,846	41,339	N/A
12/31/2023	251,163	37,082	N/A	N/A	N/A
9/30/2023	243,407	34,532	25,988	37,924	N/A
6/30/2023	235,108	31,112	N/A	N/A	N/A
3/31/2023	225,593	28,019	20,736	32,377	N/A
12/31/2022	222,187	26,383	N/A	N/A	N/A
9/30/2022	218,874	25,660	20,120	29,160	N/A
6/30/2022	216,105	24,884	N/A	N/A	N/A
3/31/2022	217,078	25,168	26,285	33,259	N/A
12/31/2021	210,718	25,681	N/A	N/A	N/A
9/30/2021	207,616	25,876	28,362	37,113	N/A
6/30/2021	202,801	25,417	N/A	N/A	N/A
3/31/2021	191,205	24,049	29,418	37,552	N/A
12/31/2020	188,779	22,374	N/A	N/A	N/A
9/30/2020	180,802	18,403	23,627	31,968	N/A
6/30/2020	174,377	16,462	N/A	N/A	N/A
3/31/2020	170,805	15,465	20,684	30,685	N/A
12/31/2019	171,206	16,678	N/A	N/A	N/A
9/30/2019	167,572	16,489	N/A	25,720	N/A
6/30/2019	163,733	15,546	N/A	N/A	N/A
3/31/2019	163,232	15,277	N/A	16,911	N/A
12/31/2018	155,224	13,391	N/A	N/A	N/A
9/30/2018	154,287	14,074	N/A	N/A	N/A
6/30/2018	154,992	14,530	N/A	N/A	N/A
3/31/2018	151,053	14,105	N/A	14,628	N/A
12/31/2017	147,618	11,701	N/A	N/A	N/A
9/30/2017	144,951	11,444	N/A	N/A	N/A
6/30/2017	141,637	10,762	N/A	N/A	N/A
3/31/2017	143,340	10,064	N/A	23,818	N/A
12/31/2016	142,509	11,213	N/A	N/A	N/A
9/30/2016	137,547	10,071	N/A	N/A	N/A
6/30/2016	134,335	12,219	N/A	N/A	N/A
3/31/2016	135,480	13,600	N/A	17,408	N/A
12/31/2015	135,044	16,847	N/A	N/A	N/A
9/30/2015	131,633	16,694	N/A	N/A	N/A
6/30/2015	124,782	15,368	N/A	N/A	N/A
3/31/2015	113,454	11,808	N/A	11,734	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CIPLA 의 연간 예상 수익 증가율(10.8%)이 saving rate(6.8%)보다 높습니다.

수익 vs 시장: CIPLA 의 연간 수익(10.8%)이 Indian 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: CIPLA 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: CIPLA 의 수익(연간 9.5%)이 Indian 시장(연간 10.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: CIPLA 의 수익(연간 9.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CIPLA의 자본 수익률은 3년 후 13.6%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/24 10:01
종가	2026/01/23 00:00
수익	2025/12/31
연간 수익	2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cipla Limited는 63명의 분석가가 다루고 있습니다. 이 중 33명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Gaurav Tinani	Ambit Capital
Nitin Bhasin	Ambit Capital
Ashwin Mehta	Ambit Capital

Cipla 향후 성장

Future 기준 점검 1/6

핵심 정보

최근 향후 성장 업데이트

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 8.7% to ₹1,391

Recent updates

Third quarter 2026 earnings: EPS and revenues miss analyst expectations

The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet

We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt

Cipla Limited to Report Q3, 2026 Results on Jan 23, 2026

Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Cipla Ltd Announces Resignation of Umang Vohra as Chief Executive Officer, Effective March 31, 2026

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

Cipla Limited to Report Q2, 2026 Results on Oct 30, 2025

Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares

Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly

First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors

Cipla Limited to Report Q1, 2026 Results on Jul 25, 2025

Full year 2025 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₹16.00 per share

Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly

Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Cipla Limited Recommends Special Dividend for the financial year ended March 31, 2025

Cipla Limited announces Annual dividend, payable on August 15, 2025

Full year 2025 earnings: EPS exceeds analyst expectations

Cipla Limited, Annual General Meeting, Jul 16, 2025

Cipla Limited (NSE:CIPLA) Investors Are Less Pessimistic Than Expected

Cipla Limited to Report Q4, 2025 Results on May 13, 2025

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Cipla Limited Receives Final Approval from United States Food and Drug Administration for New Drug Application Submit for Nilotinib Capsules 50, 150 and 200 Mg

These 4 Measures Indicate That Cipla (NSE:CIPLA) Is Using Debt Safely

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Cipla Limited Approves the Elevation of Achin Gupta as Global Chief Operating Officer, Effective 1 February 2025

Cipla Limited Announces Resignation of Rajeev Kumar Sinha as Global Chief Manufacturing Officer, Effective April 2, 2025

Cipla Limited to Report Q3, 2025 Results on Jan 28, 2025

Cipla Promoters Reportedly May Sell 1.72% Stake Worth INR 20,000 Million via Block Deal

Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions

Second quarter 2025 earnings: EPS exceeds analyst expectations

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Cipla Limited Announces Executive Appointments

Cipla Limited to Report Q2, 2025 Results on Oct 29, 2024

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Dividend increased to ₹13.00

Cipla Limited, Annual General Meeting, Aug 20, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Price target increased by 8.7% to ₹1,391

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.